301 related articles for article (PubMed ID: 16443550)
1. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).
Otsuyama K; Asaoku H; Kawano MM
Int J Hematol; 2006 Jan; 83(1):39-43. PubMed ID: 16443550
[TBL] [Abstract][Full Text] [Related]
2. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas.
Fujii R; Ishikawa H; Mahmoud MS; Asaoku H; Kawano MM
Br J Haematol; 1999 Apr; 105(1):131-40. PubMed ID: 10233376
[TBL] [Abstract][Full Text] [Related]
3. A new phenotypic classification of bone marrow plasmacytosis.
Kawano MM; Mihara K; Tsujimoto T; Huang N; Kuramoto A
Int J Hematol; 1995 Jun; 61(4):179-88. PubMed ID: 8547606
[TBL] [Abstract][Full Text] [Related]
4. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis.
Shimojima Y; Matsuda M; Gono T; Ishii W; Fushimi T; Hoshii Y; Yamada T; Ikeda S
Amyloid; 2005 Mar; 12(1):33-40. PubMed ID: 16076609
[TBL] [Abstract][Full Text] [Related]
5. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma.
Ishikawa H; Mahmoud MS; Fujii R; Abroun S; Kawano MM
Leuk Lymphoma; 2000 Sep; 39(1-2):51-5. PubMed ID: 10975383
[TBL] [Abstract][Full Text] [Related]
6. Growth mechanism of human myeloma cells by interleukin-6.
Kawano MM; Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X
Int J Hematol; 2002 Aug; 76 Suppl 1():329-33. PubMed ID: 12430875
[TBL] [Abstract][Full Text] [Related]
7. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
8. [Phenotypic analysis of myeloma cells].
Mihara K; Harada H; Kawano MM
Nihon Rinsho; 1995 Mar; 53(3):574-9. PubMed ID: 7699888
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis.
Matsuda M; Gono T; Shimojima Y; Hoshii Y; Ikeda S
Amyloid; 2003 Jun; 10(2):110-6. PubMed ID: 12964418
[TBL] [Abstract][Full Text] [Related]
10. The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells.
Tsuyama N; Ishikawa H; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Obata M; Taniguchi O; Kawano MM
Hematology; 2003 Dec; 8(6):409-11. PubMed ID: 14668037
[TBL] [Abstract][Full Text] [Related]
11. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
Kimlinger T; Witzig TE
Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic difference of normal plasma cells from mature myeloma cells.
Harada H; Kawano MM; Huang N; Harada Y; Iwato K; Tanabe O; Tanaka H; Sakai A; Asaoku H; Kuramoto A
Blood; 1993 May; 81(10):2658-63. PubMed ID: 8490175
[TBL] [Abstract][Full Text] [Related]
14. Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A
Int J Hematol; 2004 May; 79(4):364-8. PubMed ID: 15218967
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
Okura M; Ida N; Yamauchi T
Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
[TBL] [Abstract][Full Text] [Related]
18. Biological significance of heterogeneity in human myeloma cells.
Ishikawa H; Kawano MM
Int J Hematol; 1998 Dec; 68(4):363-70. PubMed ID: 9885436
[TBL] [Abstract][Full Text] [Related]
19. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells.
Huang N; Kawano MM; Harada H; Harada Y; Sakai A; Kuramoto A; Niwa O
Blood; 1993 Dec; 82(12):3721-9. PubMed ID: 8260709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
